Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

14.22
-0.0100-0.07%
Volume:9.01M
Turnover:128.56M
Market Cap:6.44B
PE:-20.15
High:14.75
Open:14.46
Low:13.95
Close:14.23
52wk High:15.30
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:0.35
T/O Rate:2.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:8.75
PE(LYR):-13.00

Loading ...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 19

Movement Alert|Iovance Biotherapeutics, Inc. Rises 8.05% in Regular Trading, Q2 Earnings Beat and UBS Target Price Upgrade Continue to Fuel Momentum

Market Focus
·
Sep 17

Iovance Biotherapeutics Price Target Raised to $15.00/Share from $13.00 by Barclays

Dow Jones
·
Sep 17

Iovance Biotherapeutics (IOVA) Receives a Buy from Barclays

TIPRANKS
·
Sep 17

U.S. Research Roundup-Celcuity, Fluence Energy, Salesforce

Reuters
·
Sep 17

Movement Alert|Iovance Biotherapeutics, Inc. Rises 8.02% in Regular Trading, Q2 Earnings Beat and UBS Target Price Upgrade Boost Sentiment

Market Focus
·
Sep 15

Iovance Biotherapeutics to Present at Upcoming Conferences

GlobeNewswire
·
Sep 04

Iovance Biotherapeutics put volume heavy and directionally bearish

TIPRANKS
·
Sep 03

Oracle Stock Leads This High Growth Watchlist For 2026

Simply Wall St.
·
Aug 23

Iovance Grants 240,135 Inducement Stock Options Priced at $8.99 Per Share

Reuters
·
Aug 22

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 22

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 22

Movement Alert|Iovance Biotherapeutics, Inc. Falls 8.06% in Regular Trading, UBS Report Flags Competitive Headwinds for Amtagvi

Market Focus
·
Aug 22

Iovance's Growth Outlook Clouded as Amtagvi Faces Competition Hurdles, UBS Says

MT Newswires Live
·
Aug 21

Iovance Biotherapeutics Price Target Raised to $7.00/Share from $4.00 by UBS

Dow Jones
·
Aug 20

Movement Alert|Iovance Biotherapeutics, Inc. Rises 9.07% in Regular Trading, Q2 Earnings Beat and UBS Price Target Raise Fuel Momentum

Market Focus
·
Aug 20

UBS Adjusts Iovance Biotherapeutics Price Target to $7 From $4, Maintains Neutral Rating

MT Newswires Live
·
Aug 20

Iovance Biotherapeutics price target raised to $7 from $4 at UBS

TIPRANKS
·
Aug 20

Iovance Biotherapeutics (IOVA) Stock Could Be Rich Following Its 217% Run

Simply Wall St.
·
Aug 20

Movement Alert|Iovance Biotherapeutics, Inc. Rises 10.03% in Regular Trading, Q2 Earnings Beat Fuels Continued Upward Momentum

Market Focus
·
Aug 20